TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
ERAS

Erasca Inc

Healthcare · Biotechnology

15.00$ +1.8% vs. previous close Closing price · As of: Sep 21, 2026

Statements

Balance Sheet

Erasca Inc (ERAS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 435 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ERAS
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
419 395 370 526 529 503 471 445 420 396 461 435
306 321 307 418 330 309 315 311 300 286 254 278
113 93 77 173 69 68 70 66 70 74 47 43
344 312 298 408 319 298 305 301 288 276 244 269
0.9 0.9 2.2 2.4 2.3 2.5 2.1 2.9 2.5 3.3
-48
80 79 82 75 79 79 72 73 73 71 68 73
27 26 30 25 30 31 25 28 29 29 27 34
7.6 7.9 4.1 8.6 4.5 9.2 4.8 4.7 4.9 5.1 5.3 5.4
3.7 2.0 2.6 2.1 2.4 0.5 2.3 1.7 3.0 1.0 2.2 2.0
-576 317 288 451 450 423 400 372 348 325 394 362
-576 -606 -641 -704 -735 -768 -799 -833 -863 -892 -1,076 -1,120
120 121 121 174 226 234 283 283 284 284 304 311

Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?